Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Agomelatine Is Effective in Reducing Insomnia in Abstinent Alcohol-Dependent Patients

Grosshans, Martin MD*; Mutschler, Jochen MD; Luderer, Mathias MD*; Mann, Karl MD*; Kiefer, Falk MD*

doi: 10.1097/WNF.0000000000000007
Original Articles

Objectives Sleep disorders are a widespread, persistent problem among alcohol-dependent patients and have been implicated in an increased risk for alcohol relapse. The melatonin-agonist agomelatine has been shown to improve overall sleep quality without daytime sedation.

Methods In an off-label therapeutic setting, 9 alcohol-dependent patients with chronic sleep disorders received nightly doses of between 25 and 50 mg of agomelatine.

Results After 6 weeks of agomelatine treatment, the Pittsburgh Sleep Quality Index global score for all patients had decreased significantly from a mean (SD) of 13.1 (1.7) to 7.8 (1.7) (t = 12.8; P = 0.00).

Conclusions Agomelatine is a preparation that is not prone to abuse. The current pilot investigation shows that agomelatine might offer the prospect of becoming a valuable addition to the pharmacological repertoire for the treatment of alcohol-dependence–associated insomnia.

*Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health Mannheim, University of Heidelberg/Medical Faculty, Mannheim, Germany; and Department of Psychiatry, Psychotherapy and Psychosomatics, Psychiatric Hospital, University of Zurich, Zurich, Switzerland.

Conflicts of Interest and Source of Funding: The authors have no conflicts of interest to declare.

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Authors Grosshans and Mutschler contributed equally to this work.

Address correspondence and reprint requests to Martin Grosshans, MD, Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, J5/68159 Mannheim, Germany; E-mail:

© 2014 by Lippincott Williams & Wilkins.